

CITATION REPORT

List of articles citing

Sumatriptan clinical pharmacokinetics

DOI: 10.2165/00003088-199427050-00002
Clinical Pharmacokinetics, 1994, 27, 337-44.

Source: <https://exaly.com/paper-pdf/25418545/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
65	Treatment of palatal myoclonus with sumatriptan. <i>Movement Disorders</i> , 1996 , 11, 748-51	7	49
64	Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 452-60	6.1	33
63	Sumatriptan: vasoactive effect on human dural vessels, demonstrated by subselective angiography. <i>Cephalalgia</i> , 1996 , 16, 224-30	6.1	27
62	Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. <i>Cephalalgia</i> , 1996 , 16, 554-9	6.1	78
61	Absorption, pharmacokinetics and metabolism of ¹⁴ C-sumatriptan following intranasal administration to the rat. <i>Xenobiotica</i> , 1996 , 26, 1273-82	2	5
60	Pearls, pitfalls, and updates for pain management. <i>Emergency Medicine Clinics of North America</i> , 1997 , 15, 399-415	1.9	22
59	Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 210-58	6.2	543
58	Validation of a liquid chromatographic tandem mass spectrometric method for the determination of sumatriptan in human biological fluids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1998 , 17, 399-408	3.5	30
57	Coronary side-effect potential of current and prospective antimigraine drugs. <i>Circulation</i> , 1998 , 98, 25-30	6.7	281
56	Sumatriptan. An updated review of its use in migraine. <i>Drugs</i> , 1998 , 55, 889-922	12.1	111
55	Rizatriptan: a new 5-HT _{1B/1D} receptor agonist for the treatment of migraine. <i>Expert Opinion on Investigational Drugs</i> , 1999 , 8, 671-85	5.9	22
54	Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks. <i>British Journal of Clinical Pharmacology</i> , 1999 , 47, 285-90	3.8	20
53	Oral Sumatriptan Pharmacokinetics in the Migraine State. <i>Clinical Drug Investigation</i> , 1999 , 17, 137-144	3.2	12
52	Current and emerging second-generation triptans in acute migraine therapy: a comparative review. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 687-700	2.9	65
51	Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 189-205	6.2	82
50	Clinically significant drug interactions with agents specific for migraine attacks. <i>CNS Drugs</i> , 2001 , 15, 105-18	6.7	38
49	The bioequivalence of standard sumatriptan tablets and two encapsulated forms of sumatriptan. <i>Pharmaceutical Medicine</i> , 2001 , 15, 21-26		5

48	Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. <i>Journal of Pharmaceutical Sciences</i> , 2001 , 90, 749-84	3.9	358
47	5HT1B/1D agonists. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 1281-2; author reply 1282-3	2.9	
46	Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 1303-10	2.9	21
45	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 2867-76	8.3	165
44	Clinical pharmacokinetics of intranasal sumatriptan. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 801-11	6.2	43
43	The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers. <i>Clinical Therapeutics</i> , 2002 , 24, 1887-901	3.5	7
42	The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. <i>Clinical Therapeutics</i> , 2002 , 24, 583-94	3.5	16
41	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 404-11	4	45
40	[Pharmacological, pharmacokinetic and clinical profile of eletriptan (Relpax), a new triptan for migraine]. <i>Folia Pharmacologica Japonica</i> , 2003 , 122, 93-101	0	
39	Pharmacokinetic interactions of topiramate. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 763-80	6.2	124
38	In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 101-5	2.9	4
37	Evidence for serotonin influencing the thalamic infiltration of mast cells in rat. <i>Journal of Neuroimmunology</i> , 2005 , 159, 20-30	3.5	10
36	True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers. <i>American Journal of Drug Delivery</i> , 2005 , 3, 133-140		9
35	Sumatriptan: update and review. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1503-14	4	15
34	Sumatriptan. 2007 , 1-6		
33	Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 489-95	2.8	24
32	Unanticipated acyloxymethylation of sumatriptan indole nitrogen atom and its implications in prodrug design. <i>Archiv Der Pharmazie</i> , 2008 , 341, 344-50	4.3	2
31	Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. <i>Drug Design, Development and Therapy</i> , 2010 , 4, 9-17	4.4	22

30	Development and evaluation of occlusive systems employing polyvinyl alcohol for transdermal delivery of sumatriptan succinate. <i>Drug Delivery</i> , 2010 , 17, 83-91	7	9
29	Teratogenic mechanisms of medical drugs. <i>Human Reproduction Update</i> , 2010 , 16, 378-94	15.8	119
28	Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro®) approved for the acute treatment of migraine, with or without aura, and cluster headaches. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 481-90	4.3	9
27	Monitoring cortical hemodynamic changes after sumatriptan injection during migraine attack by near-infrared spectroscopy. <i>Neuroscience Research</i> , 2011 , 69, 60-6	2.9	14
26	Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. <i>European Journal of Pharmaceutical Sciences</i> , 2011 , 43, 141-50	5.1	48
25	Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. <i>Journal of Headache and Pain</i> , 2011 , 12, 5-12	8.8	27
24	In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase. <i>Xenobiotica</i> , 2012 , 42, 355-62	2	11
23	Migraine and gastroparesis from a gastroenterologist's perspective. <i>Headache</i> , 2013 , 53 Suppl 1, 4-10	4.2	22
22	Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds. <i>Journal of Headache and Pain</i> , 2014 , 15, 22	8.8	17
21	Teratogenic mechanisms associated with prenatal medication exposure. <i>Therapie</i> , 2014 , 69, 13-24	3.8	11
20	Freeze drying: exploring potential in development of orodispersible tablets of sumatriptan succinate. <i>Drug Development and Industrial Pharmacy</i> , 2015 , 41, 398-405	3.6	8
19	Triptans. 2016 , 205-210		
18	Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 1229-45	4	70
17	Rapid systemic delivery of zolmitriptan using an adhesive dermally applied microarray. <i>Pain Management</i> , 2017 , 7, 559-567	2.3	13
16	Enhanced pharmacological efficacy of sumatriptan due to modification of its physicochemical properties by inclusion in selected cyclodextrins. <i>Scientific Reports</i> , 2018 , 8, 16184	4.9	13
15	Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients. <i>Cephalalgia</i> , 2020 , 40, 842-850	6.1	2
14	Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. <i>Headache</i> , 2020 , 60, 1340-1350	4.2	8
13	The role of teratogens in neural crest development. <i>Birth Defects Research</i> , 2020 , 112, 584-632	2.9	9

12	Lasmiditan: Acute Migraine Treatment Without Vasoconstriction. A Review. <i>Journal of Pharmacy Technology</i> , 2021 , 37, 244-253	0.6	
11	Periorbital Nociception in a Progressive Multiple Sclerosis Mouse Model Is Dependent on TRPA1 Channel Activation. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
10	The bioequivalence of standard sumatriptan tablets and two encapsulated forms of sumatriptan. 2001 , 15, 21		2
9	Triptans. 2006 , 3525-3528		
8	Patent Update: Central & Peripheral Nervous Systems: Antimigraine agents: July 1994 - June 1995. <i>Expert Opinion on Therapeutic Patents</i> , 1995 , 5, 1077-1086	6.8	
7	Migraine. 1997 , 141-368		
6	Transient receptor potential ankyrin 1 mediates headache-related cephalic allodynia in a mouse model of relapsing-remitting multiple sclerosis. <i>Pain</i> , 2021 ,	8	0
5	Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine.. <i>BioMed Research International</i> , 2022 , 2022, 3692065	3	0
4	Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial.. <i>Pain Management</i> , 2021 ,	2.3	2
3	Lack of Pharmacokinetic Interaction between Sumatriptan and Naproxen. 2000 , 40, 99-104		0
2	Metabolism of sumatriptan revisited. 2023 , 11,		0
1	Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes.		0